NCT02076633 trial also examines conjugated mAbs for treatment of metastatic CM patients; L19IL2 targets melanoma cells through HDAC4 and it is conjugated to IL-2; instead L19TNF is conjugated to TNFα, exerting its major effects via a preferential toxicity for the endothelial cells of the tumor-associated vasculature, therefore, increasing an antitumor immune response. This evidence concerns the gene IL2 and neoplasm.